Latest Announcements

BSE & NSE corporate filings with AI summaries

BSEGeneralRegulatory1 Oct 2026

Schneider Electric Infrastructure Ltd

Regarding news clarification on Schneider Electric, NFH join hands to explore digital energy grid applications and movement in price on Oct 1, 2026, we wish to clarify that the news pertains to another entity within Schneider group and the Company is fully conscious of its obligations under applicable laws. Enclosed herewith detailed clarification.

Schneider Electric Infrastructure Ltd clarifies that news about Schneider Electric and NFH joining hands to explore digital energy grid applications pertains to another entity within the Schneider Group, not the company itself.

Read more →📎 1 attachment
BSEGeneralExpansion1 Oct 2026

Gland Pharma Ltd

Outcome of Board Meeting held on October 01, 2026

Gland Pharma Ltd has announced the outcome of its board meeting held on October 01, 2026. The board has approved an investment of USD 21 million in Gland Pharma USA Inc., a wholly-owned subsidiary, to subscribe to 60% of the equity share capital of Novelstar Pharma Inc. Additionally, Mr. Wenjie Zhang has resigned as a Non-Executive & Non-Independent Director, and Mr. Xingli Wang has been appointed as an Additional Director. The committees of the board have been realigned in compliance with the Listing Regulations.

Read more →📎 1 attachment
BSEGeneralDivestiture1 Oct 2026

Remsons Industries Ltd

Outcome of the Board Meeting

Remsons Industries Ltd has announced the sale of its 26% stake in Aircom Remsons Automotive Private Limited, with the transaction expected to be completed by 31st October, 2026. The company has stated that the sale will not have any adverse impact on its operations.

Read more →📎 1 attachment
BSEGeneral1 Oct 2026

Valley Magnesite Company Ltd

pfa

Valley Magnesite Company Ltd has intimated BSE and CSE about non-issuance of non-convertible securities, thereby no interest/dividend/principle obligations arise.

Read more →📎 1 attachment
BSEGeneral1 Oct 2026

Saumya Consultants Ltd

pfa

Saumya Consultants Ltd has submitted an intimation under Regulation 57(5) of SEBI (Listing Obligations and Disclosure Requirements), 2015, stating that the company has not issued any non-convertible securities and therefore does not have any interest/dividend/principle obligations.

Read more →📎 1 attachment
BSEGeneralMgmt Change1 Oct 2026

Hikal Ltd

Outcome of Board Meeting held today i.e. October 01, 2026

Hikal Ltd announced the outcome of its board meeting, where Mr. Jai Hiremath stepped down as Executive Chairman, and Mrs. Sugandha Hiremath resigned as Non-Executive Director. Mr. Anish Swadi was appointed as CEO-Animal Health and Specialty Ingredients. Mr. Jai Hiremath was conferred the honorary position of 'Chairman Emeritus'.

Read more →📎 1 attachment
BSEGeneralDebt Restruc.1 Oct 2026

S.A.L. Steel Ltd

Outcomes of Board Meeting held on 01.10.2026

S.A.L. Steel Ltd has approved availing of additional Term Loan Facilities of Rs. 75,00,00,000 from Kotak Mahindra Bank Limited to part repay ICD of AIA Engineering Limited. The funds will be secured by Hypothecation on Current Assets and Movable Fixed Assets, and Equitable Mortgage on Industrial Property.

Read more →📎 1 attachment
BSEGeneralMgmt Change1 Oct 2026

Winro Commercial India Ltd

Board of Directors at its meeting held on Thursday, 1st October, 2026, inter alia, has considered and approved the following: 1. Appointment of M/s. Sudit K. Parekh & Co. LLP, as an Internal Auditor of the Company for the financial year 2026-2027. 2. Appointment of Mr. Akash Das (Membership No.: A74714) as Company Secretary & Compliance Officer of the Company w.e.f. 1st October, 2026. The meeting commenced at 12.00 p.m. and concluded at 12.30 ....

Winro Commercial India Ltd has announced the appointment of M/s. Sudit K. Parekh & Co. LLP as its Internal Auditor for FY 2026-2027 and Mr. Akash Das as Company Secretary & Compliance Officer, effective October 1, 2026.

Read more →📎 1 attachment
BSEGeneralFundraise1 Oct 2026

iSERA Lifesciences Ltd

The Board of Directors of the Company, at its meeting held today i.e. October 01, 2026, has approved the allotment of 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) fully paid-up equity shares of face value of Rs. 10/- (Rupees Ten only) each at an issue price of Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty only) per share [including a share premium of Rs. 38.20/- (Rupees Thirty-Eight and Paise Twenty only) per share] ....

iSERA Lifesciences Ltd has approved the allotment of 1,61,82,800 equity shares at Rs. 48.20 per share on a preferential basis to promoters and non-promoters.

Read more →📎 1 attachment